Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia – guidance (TA663)

Venetoclax plus obinutuzumab is recommended for untreated CLL in adults, only if there is a 17p deletion or TP53 mutation, or there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab, or bendamustine plus rituximab, is unsuitable.

Source:

National Institute for Health and Care Excellence